endTB-Q results in the face of rising bedaquiline resistance
- 16 July 2025
- journal article
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 13 (9) , 773-775
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trialThe Lancet Respiratory Medicine, 2025
- Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort studyThe Lancet Infectious Diseases, 2025
- Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort StudyClinical Infectious Diseases, 2025
- Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational studyThe Lancet Infectious Diseases, 2023
- Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal studyThe Lancet Infectious Diseases, 2022
- Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysisThe Lancet Microbe, 2021